News und Analysen
EQS-Adhoc: Ad hoc: MorphoSys’ Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction
Ozempic Might Be Helping Abbott Laboratories and DexCom Stock. Here's How.
Novo Nordisk's (NYSE: NVO) Ozempic is indicated to treat diabetes, and its wild success and household name is making a few cardiometabolic device companies rather nervous. With a powerful tool to
Ozempic Might Be Helping Abbott Laboratories and DexCom Stock. Here's How.
Novo Nordisk's (NYSE: NVO) Ozempic is indicated to treat diabetes, and its wild success and household name is making a few cardiometabolic device companies rather nervous. With a powerful tool to
EQS-Adhoc: Bayer Aktiengesellschaft: OCEANIC-AF study stopped early due to lack of efficacy
EQS-Adhoc: Bayer Aktiengesellschaft: OCEANIC-AF study stopped early due to lack of efficacy
2 Stock Split Growth Stocks to Buy and Hold
Last year, tech giant Amazon (NASDAQ: AMZN) and medical device specialist DexCom (NASDAQ: DXCM) were among the several high-profile companies to conduct stock splits. This move attracted plenty of
2 Stock Split Growth Stocks to Buy and Hold
Last year, tech giant Amazon (NASDAQ: AMZN) and medical device specialist DexCom (NASDAQ: DXCM) were among the several high-profile companies to conduct stock splits. This move attracted plenty of
Could Investing $10,000 In CRISPR Therapeutics Stock Make You a Millionaire?
All eyes have been on CRISPR Therapeutics (NASDAQ: CRSP) in recent times because the biotech company has reached a key moment. CRISPR Therapeutics and partner Vertex Pharmaceuticals are awaiting
Could Investing $10,000 In CRISPR Therapeutics Stock Make You a Millionaire?
All eyes have been on CRISPR Therapeutics (NASDAQ: CRSP) in recent times because the biotech company has reached a key moment. CRISPR Therapeutics and partner Vertex Pharmaceuticals are awaiting
Could Investing $10,000 In CRISPR Therapeutics Stock Make You a Millionaire?
All eyes have been on CRISPR Therapeutics (NASDAQ: CRSP) in recent times because the biotech company has reached a key moment. CRISPR Therapeutics and partner Vertex Pharmaceuticals are awaiting
Is Beam Therapeutics Stock a Buy Now?
When it comes to gene-editing companies on the cutting edge, Beam Therapeutics (NASDAQ: BEAM) is keen to be one of the leaders. While it's a bit of a laggard in terms of its pipeline's maturity
Is Beam Therapeutics Stock a Buy Now?
When it comes to gene-editing companies on the cutting edge, Beam Therapeutics (NASDAQ: BEAM) is keen to be one of the leaders. While it's a bit of a laggard in terms of its pipeline's maturity
3 Monster Stocks in the Making
Most, if not all, of the market's current mega-cap stocks started out much smaller. Investors who spotted their potential early had opportunities to make fortunes over time.
Which smaller stocks
You Don't Have to Pick a Winner in Biotech. Here's Why.
The biotech company that's able to deliver the next game-changing treatment might become tomorrow's winner -- and offer your portfolio a giant boost.
Problem is, it's not always easy to identify
Why CRISPR Therapeutics Stock Is Jumping Again Today
Shares of CRISPR Therapeutics (NASDAQ: CRSP) were jumping 10.1% higher as of 10:58 a.m. ET on Friday. The solid move followed Thursday's gain of more than 8%.
There's a good reason for this
Why CRISPR Therapeutics Stock Is Jumping Again Today
Shares of CRISPR Therapeutics (NASDAQ: CRSP) were jumping 10.1% higher as of 10:58 a.m. ET on Friday. The solid move followed Thursday's gain of more than 8%.
There's a good reason for this
Why CRISPR Therapeutics Stock Is Jumping Again Today
Shares of CRISPR Therapeutics (NASDAQ: CRSP) were jumping 10.1% higher as of 10:58 a.m. ET on Friday. The solid move followed Thursday's gain of more than 8%.
There's a good reason for this
Is DexCom the Next Big Growth Stock?
With shares of DexCom (NASDAQ: DXCM) falling 11% this year amid a steadily rising market, one might think that the medical device maker's growth potential is ebbing compared to its former glory. But
Is DexCom the Next Big Growth Stock?
With shares of DexCom (NASDAQ: DXCM) falling 11% this year amid a steadily rising market, one might think that the medical device maker's growth potential is ebbing compared to its former glory. But
Could DexCom Stock Help You Become a Millionaire?
Getting to $1 million is a great long-term goal for investors to target. Not only could that be a good nest egg to tap into during retirement, but you could also use that money to invest in dividend
Could DexCom Stock Help You Become a Millionaire?
Getting to $1 million is a great long-term goal for investors to target. Not only could that be a good nest egg to tap into during retirement, but you could also use that money to invest in dividend
Is Vertex Pharmaceuticals Stock a Buy Now?
If past performance guaranteed future success, Vertex Pharmaceuticals (NASDAQ: VRTX) would be one of the best biotech stocks to invest in. The drugmaker has consistently outperformed the broader
Is Vertex Pharmaceuticals Stock a Buy Now?
If past performance guaranteed future success, Vertex Pharmaceuticals (NASDAQ: VRTX) would be one of the best biotech stocks to invest in. The drugmaker has consistently outperformed the broader
Is Vertex Pharmaceuticals Stock a Buy Now?
If past performance guaranteed future success, Vertex Pharmaceuticals (NASDAQ: VRTX) would be one of the best biotech stocks to invest in. The drugmaker has consistently outperformed the broader
Where Will Medtronic Stock Be in 5 Years?
The past five years haven't been great for medical device maker Medtronic (NYSE: MDT). Normally investors would expect a stock to generate positive gains over a five-year period, but Medtronic's